{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:06:09Z","timestamp":1778544369422,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["16\/46\/01"],"award-info":[{"award-number":["16\/46\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Eve Appeal"},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR_UU_12023"],"award-info":[{"award-number":["MR_UU_12023"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a trend to increasing use of routinely collected health data to ascertain outcome measures in trials. We report on the completeness and accuracy of national ovarian cancer and death registration in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of the 202,638 participants, 202,632 were successfully linked and followed through national cancer and death registries of Northern Ireland, Wales and England. Women with registrations of any of 19 pre-defined ICD-10 codes suggestive of tubo-ovarian cancer or notification of ovarian\/tubal\/peritoneal cancer from hospital episode statistics or trial sites were identified. Copies of hospital and primary care notes were retrieved and reviewed by an independent outcomes review committee. National registration of site and cause of death as ovarian\/tubal\/peritoneal cancer (C56\/C57\/C48) obtained up to 3\u00a0months after trial censorship was compared to that assigned by outcomes review (reference standard).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Outcome review was undertaken in 3110 women on whom notification was received between 2001 and 2014. Ovarian cancer was confirmed in 1324 of whom 1125 had a relevant cancer registration. Sensitivity and specificity of ovarian\/tubal\/peritoneal cancer registration were 85.0% (1125\/1324; 95% CI 83.7\u201386.2%) and 94.0% (1679\/1786; 95% CI 93.2\u201394.8%), respectively. Of 2041 death registrations reviewed, 681 were confirmed to have a tubo-ovarian cancer of whom 605 had relevant death registration. Sensitivity and specificity were 88.8% (605\/681; 95% CI 86.4\u201391.2%) and 96.7% (1482\/1533, 95% CI 95.8\u201397.6%), respectively. When multiple electronic health record sources were considered, sensitivity for cancer site increased to 91.1% (1206\/1324, 95% CI 89.4\u201392.5%) and for cause of death 94.0% (640\/681, 95% CI 91.9\u201395.5%).<\/jats:p>\n                    <jats:p>Of 1232 with cancer registration, 8.7% (107\/1232) were wrongly designated as ovarian\/tubal\/peritoneal cancers by the registry and 4.0% (47\/1172) of confirmed tubo-ovarian cancers were mis-registered. In 656 with death registrations, 7.8% (51\/656) were wrongly assigned as due to ovarian\/tubal\/peritoneal cancers while 6.2% (40\/645) of confirmed tubo-ovarian cancer deaths were mis-registered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Follow-up of trial participants for tubo-ovarian cancer using national registry data will result in incomplete ascertainment, particularly of the site due in part to the latency of registration. This can be reduced by using other routinely collected data such as hospital episode statistics. Central adjudication by experts though resource intensive adds value by improving the accuracy of diagnoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ISRCTN:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN22488978\">ISRCTN22488978<\/jats:ext-link>\n                      . Registered on 6 April 2000\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-04968-x","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T06:06:46Z","timestamp":1611554806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials\u2014an ovarian cancer exemplar"],"prefix":"10.1186","volume":"22","author":[{"given":"Jatinderpal K.","family":"Kalsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Gentry-Maharaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Margolin-Crump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Burnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Apostolidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Massingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Karpinskyj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Woolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Widschwendter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Skates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-1732","authenticated-orcid":false,"given":"Usha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"4968_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jclinepi.2008.09.011","volume":"62","author":"A Dechartres","year":"2009","unstructured":"Dechartres A, Boutron I, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. J Clin Epidemiol. 2009;62:695\u2013702.","journal-title":"J Clin Epidemiol"},{"key":"4968_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1740774516638345","volume":"13","author":"PM Marcus","year":"2016","unstructured":"Marcus PM, Doria-Rose VP, Gareen IF, Brewer B, Clingan K, Keating K, et al. Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial? Clin Trials. 2016;13:434\u20138.","journal-title":"Clin Trials"},{"key":"4968_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ijc.23126","volume":"122","author":"T M\u00e4kinen","year":"2008","unstructured":"M\u00e4kinen T, Karhunen P, Aro J, Lahtela J, M\u00e4\u00e4tt\u00e4nen L, Auvinen A. Assessment of causes of death in a prostate cancer screening trial. Int J Cancer. 2008;122:413\u20137.","journal-title":"Int J Cancer"},{"key":"4968_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1740774509356461","volume":"7","author":"VP Doria-Rose","year":"2010","unstructured":"Doria-Rose VP, Marcus PM, Miller AB, Bergstralh EJ, Mandel JS, Tockman MS, et al. Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials. 2010;7:69\u201377.","journal-title":"Clin Trials"},{"key":"4968_CR5","doi-asserted-by":"publisher","first-page":"a2079","DOI":"10.1136\/bmj.a2079","volume":"337","author":"U Menon","year":"2008","unstructured":"Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al. Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. BMJ. 2008;337:a2079.","journal-title":"BMJ"},{"key":"4968_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"I Jacobs","year":"2016","unstructured":"Jacobs I, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945\u201356.","journal-title":"Lancet"},{"key":"4968_CR7","volume-title":"International statistical classification of disease and related health problems codes, (tenth revision) 2nd edition","author":"World Health Organisation","year":"2003","unstructured":"World Health Organisation: International statistical classification of disease and related health problems codes, (tenth revision) 2nd edition. (2003)."},{"key":"4968_CR8","volume-title":"International statistical classification of disease and related health problems codes, (tenth revision)","author":"World Health Organisation","year":"2014","unstructured":"World Health Organisation: International statistical classification of disease and related health problems codes, (tenth revision) (2014)."},{"issue":"1","key":"4968_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1\u20135.","journal-title":"Int J Gynaecol Obstet"},{"key":"4968_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37\u201346.","journal-title":"Educ Psychol Meas"},{"key":"4968_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","volume":"10","author":"U Menon","year":"2009","unstructured":"Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327\u201340.","journal-title":"Lancet Oncol"},{"key":"4968_CR12","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/sj.bjc.6690605","volume":"80","author":"N MacDonald","year":"1999","unstructured":"MacDonald N, Sibley K, Rosenthal A, Menon U, Jayarajah A, Oram D, et al. A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer. Br J Cancer. 1999;80:1826\u20137.","journal-title":"Br J Cancer"},{"key":"4968_CR13","doi-asserted-by":"publisher","first-page":"w14647","DOI":"10.4414\/smw.2018.14647","volume":"148","author":"S Wieser","year":"2018","unstructured":"Wieser S, Schmidt M, Kind AB, Heinzelmann-Schwarz VA. Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data. Swiss Med Wkly. 2018;148:w14647. https:\/\/doi.org\/10.4414\/smw.2018.14647 eCollection 2018 Jul 16.","journal-title":"Swiss Med Wkly"},{"key":"4968_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ejca.2013.11.040","volume":"51","author":"R Zanetti","year":"2015","unstructured":"Zanetti R, Schmidtmann I, Sacchetto L, Binder-Foucard F, Bordoni A, Coza D, et al. Completeness and timeliness: cancer registries could\/should improve their performance. Eur J Cancer. 2015;51:1091\u20138.","journal-title":"Eur J Cancer"},{"key":"4968_CR15","unstructured":"Internationational Classification of Diseases for Oncology http:\/\/codes.iarc.fr\/topography Accessed 1 Aug 2018."},{"key":"4968_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3346\/jkms.2009.24.1.114","volume":"24","author":"S-J Lee","year":"2009","unstructured":"Lee S-J, Bae J-H, Lee A-W, Tong S-Y, Park Y-G, Park J-S. Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci. 2009;24:114\u20139.","journal-title":"J Korean Med Sci"},{"key":"4968_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2188\/jea.JE20150010","volume":"26","author":"MN Mieno","year":"2016","unstructured":"Mieno MN, Tanaka N, Arai T, Kawahara T, Kuchiba A, Ishikawa S, et al. Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. J Epidemiol. 2016;26:191\u20138.","journal-title":"J Epidemiol"},{"key":"4968_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/00365599.2011.559950","volume":"45","author":"R Godtman","year":"2011","unstructured":"Godtman R, Holmberg E, Stranne J, Hugosson J. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45:226\u201332.","journal-title":"Scand J Urol Nephrol"},{"key":"4968_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/bjc.2016.162","volume":"115","author":"EL Turner","year":"2016","unstructured":"Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, et al. Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. Br J Cancer. 2016;115:90\u20134.","journal-title":"Br J Cancer"},{"key":"4968_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/his.12651","volume":"67","author":"N Singh","year":"2015","unstructured":"Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology. 2015;67:331\u20137.","journal-title":"Histopathology"},{"key":"4968_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2015.10.022","volume":"141","author":"N Singh","year":"2016","unstructured":"Singh N, Gilks CB, Hirschowitz L, Kehoe S, McNeish IA, Miller D, et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecol Oncol. 2016;141:195\u20138.","journal-title":"Gynecol Oncol"},{"key":"4968_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","volume":"28","author":"WG McCluggage","year":"2015","unstructured":"McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2015;28:1101\u201322.","journal-title":"Mod Pathol"},{"key":"4968_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, ESMO-ESGO Ovarian Cancer Consensus Conference Working Group, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30:672\u2013705.","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"4968_CR24","doi-asserted-by":"publisher","first-page":"400S","DOI":"10.1016\/S0197-2456(00)00095-7","volume":"21","author":"AB Miller","year":"2000","unstructured":"Miller AB, Yurgalevitch S, Weissfeld JL, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):400S\u20136S.","journal-title":"Control Clin Trials"},{"key":"4968_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2288-15-6","volume":"15","author":"NJ Williams","year":"2015","unstructured":"Williams NJ, Hill EM, Ng SY, Martin RM, Metcalfe C, Donovan JL, CAP Cause of Death Committee, et al. Standardisation of information submitted to an end-point committee for cause of death assignment in a cancer screening trial. BMC Med Res Methodol. 2015;15:6.","journal-title":"BMC Med Res Methodol"},{"key":"4968_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ijc.27651","volume":"132","author":"S Walters","year":"2013","unstructured":"Walters S, Maringe C, Butler J, Brierley JD, Rachet B, Coleman MP. Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership. Int J Cancer. 2013;132:676\u201385.","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"4968_CR27","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1038\/bjc.2015.49","volume":"112","author":"S McPhail","year":"2015","unstructured":"McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112(Suppl 1):S108\u201315.","journal-title":"Br J Cancer"},{"key":"4968_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13063-017-1995-3","volume":"18","author":"BC Kahan","year":"2017","unstructured":"Kahan BC, Feagan B, Jairath V. A comparison of approaches for adjudicating outcomes in clinical trials. Trials. 2017;18:266. https:\/\/doi.org\/10.1186\/s13063-017-1995-3.","journal-title":"Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04968-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-04968-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04968-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T06:17:13Z","timestamp":1611555433000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04968-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4968"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04968-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-31549\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-31549\/v2","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the UK North West Multicentre Research Ethics Committees (North West MREC 00\/8\/34) on 21 June 2000 with site-specific approval from the local regional ethics committees and the Caldicott guardians (data controllers) of the primary care trusts. All trial participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"UM has stock ownership in Abcodia awarded to her by UCL. IJ is a co-inventor of the Risk of Ovarian Cancer Algorithm (ROCA). The ROCA has been licenced to Abcodia Ltd. by the owners of the ROCA, Massachusetts General Hospital (MGH) and Queen Mary University of London (QMUL). IJ has a financial interest in Abcodia Ltd. as a shareholder and director and is entitled to a royalty payment via MGH and QMUL from any commercial use of the ROCA. He is a trustee (2012\u20132014) and Emeritus Trustee (2015 to present) for The Eve Appeal. SJS co-developed the risk of ovarian cancer algorithm with all rights assigned to MGH and QMUL. MGH has co-licenced software to Abcodia implementing the algorithm. SJS receives personal fees from the LUNGevity Foundation and SISCAPA Assay Technologies as a member of their Scientific Advisory Boards and from Abcodia as a consultant. SA is funded by a research grant from Abcodia. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}